| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Human |
| Target | DLL3 andCD3 |
| Clinical data | |
| Trade names | Imdelltra |
| Other names | AMG757; AMG-757, tarlatamab-dlle |
| AHFS/Drugs.com | Multum Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4664H7139N1259O1454S34 |
| Molar mass | 105202.82 g·mol−1 |
Tarlatamab, sold under the brand nameImdelltra, is ananti-cancer medication used for the treatment of extensive-stagesmall cell lung cancer.[4] It is abispecific T-cell engager that bindsdelta-like ligand 3 and CD3.[4]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[5]
Tarlatamab was approved for medical use in the United States in May 2024.[5][6] The USFood and Drug Administration (FDA) considers it to be afirst-in-class medication.[7]
Tarlatamab isindicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.[4][5]
The prescribing information for tarlatamab includes aboxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).[4]
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[5] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.[5]
Efficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study.[5] Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded.[5] Participants received tarlatamab until disease progression or unacceptable toxicity.[5]
The FDA granted the application for tarlatamabpriority review,breakthrough therapy, andorphan drug designations.[5]
Tarlatamab was approved for medical use in the United States in May 2024.[5][6][8][9]
Tarlatamab is theinternational nonproprietary name[10] and theUnited States Adopted Name.[11]
This article incorporates text from this source, which is in thepublic domain.
